Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EX039 in Mild Alzheimer's Disease
NCT05413655Phase 2Recruiting
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of EX-039 in Alzheimer's disease (AD). Started Aug 2022; status: recruiting.
02
Drugs
EX-039
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05413655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05413655.